Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 121–144 of 164
Vascular age acceleration, measured through a quantitative model, independently predicts cardiovascular disease risk beyond chronological age, with a 21–25% increased risk in those showing accelerated vascular aging. This metric enables earlier identification of individuals requiring intervention before overt disease manifestation.
A 20-year follow-up of the ACTIVE trial found that speed-of-processing training with booster sessions reduced dementia diagnoses in older adults, a rare signal of efficacy in prevention research anchored to clinical diagnoses rather than cognitive test scores alone.
Mimio Health's fasting-mimetic therapy produced biomarker changes consistent with fasting physiology—including improved metabolic markers and enhanced fat metabolism—without dietary modification. The intervention was well tolerated and represents a pharmacological approach to accessing metabolic benefits traditionally associated with caloric restriction.
Dehydroepiandrosterone sulfate (DHEAS) levels correlate with subjective health perception in a longitudinal population study, suggesting this adrenal steroid may serve as a physiological marker for how individuals experience their own health status. The finding bridges objective biochemistry with subjective well-being, relevant to understanding which biomarkers meaningfully predict health experience across the lifespan.
Electrocardiogram-derived heart age models show moderate agreement with chronological age but demonstrate significant individual variation, with predictive accuracy for cardiovascular outcomes varying substantially depending on the specific model used. This suggests ECG-based age estimates require careful interpretation and cannot yet replace traditional risk assessment tools.
Single-cell profiling of nearly 1,000 individuals demonstrates that immune aging follows distinct cellular and transcriptional trajectories between sexes, with female participants showing more pronounced cellular and molecular remodeling than males. This finding reveals that sex-based differences in immune function are not uniform across aging and must inform how we assess and support immune resilience across the lifespan.
Meal timing correlates with biological aging rates across multiple organs, with optimal outcomes occurring when the first meal is consumed before 8 a.m. and the last meal between 3 p.m. and 7 p.m., while extended feeding windows and late first meals accelerate aging markers in the heart and liver. This relationship varies substantially by age, sex, and metabolic health status, suggesting meal timing functions as a modifiable variable in aging trajectories.
BGE-102, an oral NLRP3 inhibitor, demonstrated rapid and substantial reductions in high-sensitivity C-reactive protein (85–86% median reduction) and inflammatory markers in a Phase 1 trial, with 87–93% of treated participants normalizing hsCRP levels and no serious adverse events reported. This early evidence suggests a therapeutic approach to systemic inflammation that may have relevance to age-related disease prevention.
GADD45B deletion induces DNA methylation patterns resembling age-associated changes in hematopoietic stem cells, yet these methylation alterations occur without functional decline. The research distinguishes between methylation signatures and actual loss of HSC capacity, providing a resource to identify which methylation sites causally drive age-related hematopoietic dysfunction.
A large epidemiological analysis of 15,050 participants found that higher intake of vitamins, particularly C and B2, correlates with slower biological aging as measured by multiple aging biomarkers. The association remained significant after adjustment for socioeconomic and lifestyle factors, suggesting a direct relationship between vitamin adequacy and the rate of biological aging.
Higher PM 2.5 and PM 10 exposure accelerates biological aging markers in older adults, but adherence to plant-based dietary patterns significantly attenuates this acceleration. The protective effect is strongest in individuals with genetic predisposition to shorter lifespan.
Plasma extracellular vesicles carrying microRNAs show age-specific expression patterns that correlate with biological aging across the human lifespan. These circulating biomarkers may serve as measurable indicators of systemic aging processes and inform stratification of longevity risk.
Oxidative damage biomarkers correlate with frailty in older women, providing measurable indicators of cellular stress that precede functional decline. Identifying these markers enables earlier intervention before frailty manifests clinically.
This article reports on pharmaceutical market expansion in fallopian tube cancer treatment through targeted therapies and companion diagnostics, driven by improved genetic testing for BRCA1/BRCA2 mutations and earlier detection. The development of biomarker-driven, personalized approaches addresses a rare gynecologic malignancy where prevention and early intervention now have clinical pathways.
Interferon-gamma (IFN-γ), a common immune signaling molecule, emerges as a blood-based biomarker capable of distinguishing Alzheimer's disease from healthy aging with high accuracy, particularly in individuals carrying the APOE ε4 genetic variant. The finding suggests a scalable pathway for early detection and monitoring, shifting the disease profile toward immune-driven pathology.
Microglial and astrocytic cells in an Alzheimer's disease mouse model exhibit progressive senescence linked to amyloid pathology, while neurons remain unaffected. This cell-type-specific senescence signature identifies glial cells as primary targets for senescence-directed therapeutic intervention in Alzheimer's disease.
C2N Diagnostics and Codex Genetics are expanding access to PrecivityAD2, a blood test measuring amyloid biomarkers to assess Alzheimer's risk in asymptomatic or early-symptomatic individuals. Early detection via non-invasive biomarker assessment enables intervention before cognitive decline becomes clinically apparent, shifting Alzheimer's management from reactive to preventive.
Gordian Bio describes a scalable in-vivo mosaic screening platform that uses barcoded CRISPR libraries and single-cell readouts to establish causal gene-disease relationships in living organisms. This approach accelerates therapeutic target discovery by testing multiple genetic perturbations simultaneously, reducing experimental variation and improving efficiency compared to traditional methods.
Proteomic analysis identifies distinct and overlapping protein signatures across different manifestations of cerebral small-vessel disease, revealing shared involvement of vascular, immune, and neuronal pathways. Plasma protein panels show predictive capacity for cerebrovascular events, establishing measurable biomarkers for disease stratification and risk assessment.
Brain structural similarity patterns on MRI predict individual rates of cognitive decline better than chronological age alone, suggesting that neural architecture itself encodes aging trajectories. This offers a measurable biological marker for identifying cognitive vulnerability before clinical decline becomes apparent.
Telomerase (TERT) in myeloid cells prevents senescence and pro-inflammatory polarization through mechanisms independent of telomere length. Loss of myeloid TERT drives foam cell formation, dyslipidemia, pulmonary fibrosis, and cardiac dysfunction—establishing TERT as essential for preventing aging-associated multi-organ pathology.
Preclinical Parkinson's research has relied on young animal models and acute toxin paradigms that fail to capture the disease's age-dependent biology. The PD-AGE roadmap calls for aging-integrated models—using genetic systems with gradual phenotypes and crossing them with accelerated aging strains—to better reflect how Parkinson's actually develops in older humans and improve translational reliability.
Emagene.life and Adam Health have partnered to deliver AI-driven men's health optimization across Southeast Asia, integrating wearable biodata tracking with functional medicine assessment. The collaboration centers on detecting physiological decline through early biomarkers—particularly nocturnal erectile function as a cardiovascular and metabolic health indicator—before symptomatic disease emerges.
Meal timing significantly influences biological aging rates, with earlier first meals (before 8 a.m.) and last meals between 3 p.m. and 7 p.m. associated with slower aging in heart, liver, and whole-body measures. The relationship is nonlinear and depends on age, sex, caloric intake, and organ-specific responses.
